



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai 400 001.

Date: 30.04.2025

Dear Sir/Madam,

Sub: Reporting of Annual Disclosure to be made by an entity identified as a Large Corporate:

Unit: Vista Pharmaceuticals Limited (BSE Scrip Code: 524711)

This is with reference to the above SEBI Circular dated 26th November, 2018 and in continuation to the Exchange Circular dated April 11, 2019, with regard to fund raising by issuance of debt securities by large entities (LC) and disclosures and compliances thereof by such Large Corporates (LC).

In this connection, we submit that our company Vista Pharmaceuticals Limited is not coming under the Large Corporate (LC) category as per the framework provided in the aforesaid circular.

This is for your information and records.

Thanking you.

Yours faithfully,
For Vista Pharmaceuticals Limited



Dhananjaya Alli
Executive Director
Din: 00610909



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264
Plot No. 104, Ravindra Co Operative Society, Guttala Begumpet,
Kakateeya Hills, Hyderabad - 500 081. Telangana, INDIA. Tel : 040 - 23741585
E-mail : admin.hyd@vistapharmaceuticals.com @www.vistapharmaceuticals.com

Annual Disclosure to be made by an entity identified as a Large Corporate


1. Name of the Company: Vista Pharmaceuticals Limited
2. CIN: L24239TG1991PLC012264
3. Report filed for FY: 2024-25
4. Details of the Current block (all figures in Rs crore):

Si. No	Particulars	Details
i.	2-year block period (Specify financial years)	F.Y-2024-25 F.Y-2025-26
ii.	Incremental borrowing done in FY (2024-25) (a)	Nil
iii.	Mandatory borrowing to be done through debt securities in FY (2024-25) (b) = (25% of a)	Not Applicable
iv.	Actual borrowing done through debt securities in FY (2024-25) (c)	Nil
v.	Quantum of (d), which has been met from (c) (e)	Not Applicable
Vi,	Shortfall, if any, in the mandatory borrowing through debt securities for FY (2024-25) {after adjusting for any shortfall in borrowing for FY (2023-24) which was carried forward to FY (2024-25)} (f)= (b)-[(c)-(e)] {If the calculated value is zero or negative, write "nil"}	Not Applicable

5. Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore):

Si. No	Particulars	Details
i.	2-year block period (Specify financial years)	F.Y-2024-25 F.Y-2023-24
ii.	Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d)-(e)}#	Not Applicable

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.




Dhananjaya Alli
Executive Director

T.S.I.I.C. Industrial Estate, Gopalaipalli (Village), Narketpalli (Mandal), Nalgonda Dist., Telangana - 508254
Tel : +91 91777 15305 Telefax : 08682-272551 E-mail : admin.nkp@vistapharmaceuticals.com